Pomerantz Files Class Action Against Regencell Bioscience Holdings and Certain Officers

Pomerantz LLP announced on June 18, 2026 that it has filed a class action lawsuit against Regencell Bioscience Holdings Limited (NASDAQ: RGC) and certain of the company's officers. The complaint was filed in United States District Court.

The Filing

New York-based Pomerantz LLP named Regencell Bioscience Holdings Limited and certain unnamed officers as defendants. Regencell trades on the Nasdaq under the ticker RGC. The firm's announcement did not identify the specific officers named in the action, nor did it disclose the district in which the case was filed beyond the federal court system.

What the Source Discloses

The announcement, distributed via PRNewswire, confirms a class action has been initiated. Beyond the identities of the corporate defendant and the general category of individual defendants — current or former officers — the publicly available portion of the release does not specify the claims alleged, the proposed class period, or any dollar figures attached to the suit.

What Investors Should Track

Class actions filed against publicly traded companies and their officers typically allege that shareholders suffered harm during a defined period. Investors in RGC should monitor the docket for a fuller complaint, which would disclose the specific legal theories, the class period, and which officers are named. Pomerantz LLP is headquartered in New York.

The source for this article is limited to Pomerantz LLP's June 18, 2026 announcement. Material details including the nature of the claims, the proposed class period, and named individual defendants were not available in the published summary. Readers should consult primary court filings for the complete record.